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Introduction
Behavioral interventions for treating the current pandemic of  obesity, such as diet and exercise, although 
health-enhancing, suffer from poor compliance and limited long-term efficacy, in part due to compensatory 
metabolic adaptations (1). Similarly, responses to currently approved medical therapies are limited, with 
30%–60% of  patients failing to achieve 5% weight loss over a 3-month period of  treatment (2). Bariatric 
surgery has a more sustained effect on body weight and comorbidities, such as type 2 diabetes and cardio-
vascular disease risk, but is a major surgical procedure with risk of  complications, including nutritional 
deficiencies and anemia (3). For all of  these reasons, further research is needed on pharmacologic strategies 
for inducing sustained weight loss and metabolic health in obese subjects.
Fumagillin is a natural product isolated from Aspergillus fumigatus in 1949 and shown decades later to be 
an inhibitor of  angiogenesis (4, 5). Methionine aminopeptidase type 2 (MetAP2) was identified as a molecu-
lar target of  fumagillin in 1997 (6). Both rodent and human studies indicate that fumagillin and fumagillin-re-
lated compounds decrease food intake and hunger. In addition, MetAP2 inhibitors have been hypothesized to 
decrease angiogenesis in adipose tissue, and this has been suggested to lead to loss of  fat mass. Indeed, in mice 
with diet-induced obesity (DIO), chronic fumagillin administration results in reduced adipose blood vessel 
density and mass (7). However, this effect also is seen in response to caloric restriction and, thus, could be 
due to vascular remodeling associated with reductions in fat cell size. MetAP2 inhibitors impact intracellular 
signaling pathways, notably ERK 1/2, providing one explanation for their observed lipid-lowering effects (8). 
Fumagillin and fumagillin analogs also have been reported to lower leptin levels in concert with reduced fat 
mass and to increase levels of  FGF21 and adiponectin (9). Nonetheless, the mechanisms by which fumagillin 
produces sustained lowering of  food intake and body weight in both rodents and humans remain ill defined. 
In the present report, we examine how inclusion of  fumagillin in a high-fat (HF) diet fed to Wistar rats causes 
changes in feeding behavior and energy expenditure compared with pair-fed controls. Our analyses include 
tests of  whether the gut microbiota is involved in mediating these effects. Together, our results unveil fumagil-
lin-regulated behavioral and physiological networks that regulate energy balance.
Current obesity interventions suffer from lack of durable effects and undesirable complications. 
Fumagillin, an inhibitor of methionine aminopeptidase-2, causes weight loss by reducing food 
intake, but with effects on weight that are superior to pair-feeding. Here, we show that feeding of 
rats on a high-fat diet supplemented with fumagillin (HF/FG) suppresses the aggressive feeding 
observed in pair-fed controls (HF/PF) and alters expression of circadian genes relative to the HF/
PF group. Multiple indices of reduced energy expenditure are observed in HF/FG but not HF/PF rats. 
HF/FG rats also exhibit changes in gut hormones linked to food intake, increased energy harvest by 
gut microbiota, and caloric spilling in the urine. Studies in gnotobiotic mice reveal that effects of 
fumagillin on energy expenditure but not feeding behavior may be mediated by the gut microbiota. 
In sum, fumagillin engages weight loss–inducing behavioral and physiologic circuits distinct from 
those activated by simple caloric restriction.
2insight.jci.org   https://doi.org/10.1172/jci.insight.99453
R E S E A R C H  A R T I C L E
Results
Effect of  diet interventions on body weight and food intake. To study the mechanism of  weight loss induced by 
fumagillin, we caused DIO in young (6-week-old) Wistar rats by feeding them a HF diet for 12 weeks. A 
control group was fed standard chow (SC) for the same time period. At 12 weeks, the HF group had a 157% 
± 28% (mean ± SD) increase in body weight relative to their starting weight, compared with 116% ± 12% 
in the SC group (n = 82 in the HF group; n = 26 in the SC group; P = 1.7 × 10–10; Figure 1A). As expected, 
the HF group consumed significantly more calories over the 12-week feeding period per animal compared 
with the SC group (P = 0.0001; Figure 1B).
After this 12-week feeding period, animals were divided into 4 intervention groups, with various studies 
performed on subgroups of  animals at 2, 4, and 8 weeks after the start of  the interventions: (i) groups of  
HF rats continued on HF diet ad libitum; (ii) groups of  SC rats continued on SC diet ad libitum; (iii) groups 
of  HF rats switched to a HF diet containing 80 mg fumagillin/kg of  HF food (HF/FG) (see Methods for 
details of  fumagillin preparation and dosing); and (iv) groups of  HF rats pair-fed on HF diet (HF/PF) to 
match the reduced rate of  food intake observed in the HF/FG group (n = 26 rats/treatment group for HF, 
HF/PF, and SC for 2-week treatments; n = 34 for 2-week HF/FG treatment; n = 13 for 8-week HF, HF/PF, 
and SC treatments; n = 17 for 8-week HF/FG treatment. Four-week intervention studies, including n val-
ues, are summarized later in the sequence of  experiments). Supplemental Table 1 (supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.99453DS1) provides complete infor-
mation about diets used in this study.
Animals fed HF or SC diets gained weight at similar rates for the 8-week intervention period (P = 
0.38; Figure 1C). In contrast, rats fed the HF/FG diet experienced dramatic and sustained weight loss, 
with decreases in body weight of  –8.4% ± 1.7% after 2 weeks, –10.7% ± 3.1% after 4 weeks, and –9.4% ± 
4.5% after 8 weeks of  intervention, respectively. HF/PF caused a similar initial rate of  weight loss as the 
HF/FG diet, but the effect was transient, with reductions in body weight of  –5.9% ± 2.3% after 2 weeks, 
–6.6% ± 3.8% after 4 weeks, and –3.3% ± 4.4% after 8 weeks of  intervention (Figure 1C). Data shown in 
Figure 1C summarize changes in body weight as percent weight loss compared with starting weight, with 
each rat serving as its own control. Measurement of  food intake during the interventions, expressed both 
as grams of  food consumed/rat and kcal/g body weight, demonstrated a sharp decrease in food intake 
in the HF/FG group over the first 2 weeks of  intervention, with a gradual return toward the rate of  food 
intake of  the HF group in weeks 2–8 (Figure 1, D and E). Calculation of  average caloric intake over the 
full 8 weeks of  intervention confirmed that the HF/FG and HF/PF groups had the same rate of  food 
intake, which — for both groups — was significantly lower than the rate of  food intake for the HF group 
fed ad libitum (P < 0.05) (Figure 1F).
Although we believe that showing weight loss data normalized to each animal’s starting weight as in 
Figure 1 is the most appropriate means of  displaying our data, we also provide primary data for weight loss 
in grams/rat for all groups used in this study in Supplemental Figures 1–3, delineated for the 2-week, 4-week, 
and 8-week intervention time points. Importantly, a simple sum of grams of  weight lost per rat demonstrates 
a significantly greater weight loss in the HF/FG group compared with the HF/PF group over all 3 interven-
tion time periods (Supplemental Figure 1D, Supplemental Figure 2D, and Supplemental Figure 3D). This 
was true despite the fact that the HF/FG and HF/PF groups consumed exactly the same amount of  food in 
grams/rat over the full study period (Figure 1D). Finally, we also measured water intake in a group of  rats fed 
on HF diet for 12 weeks and switched to HF/FG diet for 2 weeks. Water intake stayed constant during the 
2 weeks of  HF/FG feeding, while food intake and body weight were falling (Supplemental Figures 4, A–C), 
allowing us to conclude that the weight loss induced by fumagillin was not due to reduced water intake.
Fumagillin reduces adiposity and improves insulin sensitivity. The HF/FG group had significantly reduced 
size and weight of  epididymal white adipose tissue (EWAT) as early as 2 weeks after initiation of  treatment 
relative to the HF group, while the effect of  HF/PF was not significant until 8 weeks of  intervention (Fig-
ure 2A). In contrast, HF/PF rats had significantly reduced liver weights at 2 and 8 weeks relative to the HF 
or HF/FG groups, whereas HF/FG feeding had no effect on this measure at either time point (Figure 2B).
Hyperinsulinemic-euglycemic clamp analysis revealed that insulin sensitivity was improved similarly and 
significantly in HF/FG- and HF/PF-treated rats compared with the HF group, at both the 2-week and 8-week 
time points, as reflected by higher glucose infusion rates (GIR) (Figure 2C). These results were confirmed by 
decreased homeostatic model assessment (HOMA) scores (a factorial of  insulin × glucose measured in the 
fasted state) in the HF/FG and HF/PF groups relative to the HF group at 8 weeks (Supplemental Table 2).
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Fumagillin suppresses energy expenditure and alters feeding behavior. To begin to assess factors that may 
influence the differential effects of  HF/FG and HF/PF on body weight, we measured energy expen-
diture and physical activity in metabolic cages. Food was provided to all groups of  animals once daily 
at approximately 1 pm, 6 hours after the start of  the 12-hour light cycle (Zeitgeber time [ZT] 6:00). 
Striking differences in metabolic cage variables were observed in the HF/FG versus HF/PF groups at 
both 2 and 8 weeks of  intervention. Animals in the HF/PF group ate their food quickly and aggres-
sively shortly after it was placed in the cage. This was reflected by sharp spikes in oxygen exchange rate 
(VO2, volume of  oxygen consumed), physical activity, heat production, and respiratory exchange ratio 
(RER) that occurred shortly after provision of  food (Figures 3 and 4). In contrast, HF/FG-treated rats 
did not respond to provision of  food in the same fashion and exhibited no sudden changes in VO2, 
physical activity, heat production, or RER. Visual inspection of  rats in the 2 groups revealed a noncha-
lant approach of  the HF/FG-treated rats to feeding following meal provision, compared with a more 
excited and immediate response of  the HF/PF group.
Figure 1. Fumagillin reduces caloric intake and body weight in obese rats. (A) Body weight changes (% increase relative to starting weight) over the initial 
12 weeks of feeding of HF or SC diets. Data are means of n = 86 for the HF group and n = 26 for the SC group. Weight gain was significantly different in the 
HF versus SC animals after 1 week of feeding (P < 0.0012). (B) Mean caloric intake over the 12-week feeding period in HF and SC diet groups, expressed as 
Kcal/rat/week. The difference between groups are significant at all time points (P < 0.0004). (C) After the initial 12-week feeding period, animals were 
divided into 4 intervention groups: (i) HF rats continued on HF diet ad libitum (HF); (ii) SC rats continued on SC diet ad libitum (SC); (iii) HF rats switched 
to HF/FG diet ad libitum (HF/FG); (iv) HF rats pair-fed on HF diet (HF/PF) to match food intake of the HF/FG group. Body weight change is expressed as 
percent change relative to the start of the intervention period. Beginning at day 5 of intervention, the HF/FG and HF/PF rats lost weight compared with 
HF or SC (P = 0.04–0.00001). Data represent n = 26 for HF, HF/PF, and SC groups at 2 weeks of diet intervention and an n = 13 for these groups between 
2–8 weeks of intervention. For HF/FG, n = 34 at 2 weeks of diet intervention and n = 17 from 2–8 weeks. (D) Mean daily food intake in the 4 intervention 
groups described in C expressed as grams of food consumed/rat. (E) Daily caloric intake for the groups described in C, expressed as Kcal/gram body weight/
day. The HF and SC groups and the HF/FG and HF/PF groups were not different at any time point. Consumption of HF and HF/FG diets were significantly 
different (P < 0.024) from day 2–38, except for days 13, 19, 20, 27, 32, 36, and 37. Consumption of HF food by the HF and HF/PF groups were significantly 
different (P < 0.015) from day 1–38, except for days 20, 27, 32, 36, and 37. (F) Mean daily caloric intake, Kcal/gram body weight/day, for groups described in 
C. Data are mean ± SD, with *P < 0.05 when compared with either HF or SC group. Two-tailed, unpaired t tests were performed in all panels. P < 0.05 with 
a Bonferroni correction was used to define statistical significance among groups.
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In addition to showing the primary profiles for VO2, physical activity, RER, and heat production, Fig-
ures 3 and 4 summarize each of  those measurements as AUCs during the light cycle, the dark cycle, and the 
entire 24-hour observation period and provide the results of  statistical tests of  observed differences between 
the treatment groups. Remarkably, VO2 was significantly reduced during the light cycle, the dark cycle, and 
the full observation period, at both the 2-week and 8-week time points, in the HF/FG group compared with 
the HF/PF group (Figure 3A). Heat production was also significantly lower in the HF/FG group than 
in the HF/PF group at both time points (Figure 3B). Physical activity trended lower at 2 weeks and was 
significantly lower at 8 weeks in the HF/FG compared with HF/PF group (Figure 4A). RER was similar 
in the HF, HF/FG, and HF/PF groups in the light and dark cycles and over the full observation period, 
whereas, as expected, animals fed the grain-based SC diet had a higher RER than any of  the HF groups 
at both the 2-week and 8-week time points (Figure 4B). Together, these data demonstrate that the dramat-
ic and sustained weight loss in the HF/FG group compared with the HF/PF group is not explained by 
increased physical activity or energy expenditure. To the contrary, energy expenditure and physical activity 
were lower in HF/FG rats.
To investigate if  the more relaxed feeding response of  HF/FG rats was related to a taste aversion 
response to the fumagillin-supplemented food, we performed a diet preference test. When single-caged, 
SC-fed rats were given a mixture of  equal portions of  HF and HF/FG diets (the 2 diets are distinguishable 
by added food coloring), they began by eating approximately equal portions of  each but then shifted to 
preferential consumption of  the HF diet (Supplemental Figure 4D). This suggests that the HF/FG food 
Figure 2. Fumagillin reduces white adipose tissue weights and improves insulin sensitivity in obese rats. Diet-induced obesity was induced in Wistar 
rats by feeding a high-fat (HF) diet for 12 weeks. A control group was fed a standard chow (SC) diet for the same time period. After the feeding period, rats 
were then subjected to dietary intervention periods of 2 or 8 weeks as described in Figure 1C. (A) Epididymal white adipose tissue (EWAT) weights for the 
groups described in Figure 1C, fed the indicated diets for 2 or 8 weeks (2W, 8W, respectively). +P < 0.05 compared with HF group after 2 weeks of diet inter-
vention. @P < 0.05 when compared with HF and HF/FG groups after 2 weeks of diet intervention. #P < 0.05 when compared with the other 3 groups after 8 
weeks of diet intervention. (B) Liver weights for the groups described in Figure 1C, fed the indicated diets for 2 or 8 weeks (2W, 8W, respectively). +P < 0.05 
when compared with HF group after 2 weeks of diet intervention. *P < 0.05 when compared with HF group after 8 weeks of diet intervention. In A and 
B, tissue weights were normalized to body weight. n = 6 for each group. Data are presented as mean ± SD. (C) Glucose infusion rate during hyperinsuline-
mic-euglycemic clamps. A cohort of animals treated as described in Figure 1C were used. Data are presented as mean ± SD for n = 5–7 rats per group. +P < 
0.05 when compared with other groups after 2 weeks of diet intervention. *P < 0.05 when compared with other groups after 8 weeks of diet interventions. 
For A–C, 2-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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induces temporary taste aversion, possibly contributing to the lower food consumption in the early phases 
of  the feeding study. However, this effect is not sustained, as the animals increase consumption of  HF/
FG food, ultimately returning to near the rate of  consumption exhibited by the HF group (Figure 1C). 
We also emphasize that this apparent diet preference for HF relative to HF/FG food is unlikely to explain 
the relaxed feeding behavior of  HF/FG-fed rats. This is supported by a recent study in which injection of  
a different MetAP2 inhibitor, beloranib, caused consistent suppression of  “frantic” eating and hyperpha-
gia-related behaviors in a cohort of  human subjects with Prader-Willi syndrome (10). Given that the drug 
was injected in those studies, the suppression of  food-seeking behavior cannot be ascribed to direct taste 
aversion caused by oral ingestion of  a MetAP2 inhibitor–containing diet.
Fumagillin treatment affects feeding rhythm and circadian gene expression. To further investigate the effects 
of  fumagillin on feeding behavior, food intake was monitored multiple times daily after provision of  food 
at ZT6:00 (1 pm). During the first 5 days of  the experiment, food was provided ad libitum for both the 
HF and HF/FG groups. Once the rate of  food intake was established for the HF/FG group over this time 
period, the HF/PF group and HF/FG groups were given an amount of  food to closely model consump-
tion of  the HF/FG group (55% of  the food consumed by animals in the ad libitum fed HF group). This 
amount was slightly more than actually consumed by the HF/FG group during ad libitum feeding (52% 
of  the HF group, average per day at these early-intervention time points). We reasoned that providing 
Figure 3. Fumagillin feeding affects oxygen exchange rate and heat production. The groups described in Figure 1C were studied in metabolic cages at 2 weeks 
or 8 weeks after the start of the dietary intervention period. (A) Oxygen exchange rate (VO2) and (B) heat production (HEAT) are represented. For these mea-
surements, upper panels represent data collected from the animals after 2 weeks and lower panels after 8 weeks of intervention. Left panels are raw data, 
and right panels summarize measurements as AUC. All groups received food once daily at ZT6:00 (1 pm), as shown by the downward-pointing arrows. Data for 
AUCs in the right panels are presented as mean ± SD for n = 7 for each group. *P < 0.05 when compared with the other 3 groups; +P < 0.05 when compared with 
HF/PF group. Two-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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the same food portions to the HF/PF or HF/FG groups would control for anxiety responses elicited by 
perception of  limited food availability.
Animals in the ad libitum–fed HF group ate predominantly during the dark cycle from ZT14:00–2:00 
(9 pm to 9 am) and consumed far less food in the light periods from ZT6:00–10:00 (1–5 pm) and ZT10:00–
14:00 (5–9 pm) (P = 5.7 × 10–15; Figure 5A). In the HF/FG group, food intake was reduced in all 3 time 
periods relative to the HF group (P ≤ 0.0024), although the general pattern of  greater food consumption 
in the dark than in the light was retained (Figure 5B). Over the course of  several days, animals in the HF/
PF group developed a distinct feeding pattern compared with the HF/FG or HF groups, with most food 
consumed in the first 8 hours in the light phase (Figure 5C). These data are consistent with the metabolic 
cage experiments summarized in Figures 3 and 4 that document increased energy expenditure and physical 
activity (mostly related to feeding) in the HF/PF group in the time period immediately after provision of  
food at ZT6:00 (1 pm).
These results suggest that fumagillin may serve to suppress aggressive feeding behavior under conditions 
of  single-meal feeding. To determine if  fumagillin also influenced genes involved in control of  circadian 
rhythms related to food intake, we measured mRNAs encoding positive (Clock and Bmal1) and negative (Per1) 
regulators of  the circadian clock in different sections of  gastrointestinal tract and liver, as well as in WAT, all 
of  which have been reported to contain a functional clock system (11–13). HF/PF rats had lower expression 
Figure 4. Fumagillin feeding affects ambulatory activity and has an acute effect on respiratory exchange rate (RER). The groups described in Figure 1C 
were studied in metabolic cages at 2 weeks or 8 weeks after the start of the dietary intervention period. (A) Ambulatory activity (XAMB) and (B) respirato-
ry exchange rate (RER) are represented. For these measurements, upper panels represent data collected from the animals after 2 weeks and lower panels 
after 8 weeks of intervention. Left panels are raw data, and right panels summarize measurements as AUC. All groups received food once daily at ZT6:00 
(1 pm), as shown by the downward-pointing arrows. Data for AUCs in the right panels are presented as mean ± SD for n = 7 for each group. *P < 0.05 when 
compared with the other 3 groups; +P < 0.05 when compared with HF/PF group. Two-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni 
correction was used to define statistical significance among groups.
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of Clock and Bmal1 and increased levels of  Per1 mRNA in the stomach, colon, liver, and multiple regions of  
the small intestine compared with either the HF or HF/FG groups, whereas group differences were either 
not apparent or present as weak trends in epididymal or mesenteric WAT (Figure 5D). These findings suggest 
that fumagillin-induced alterations in feeding behavior and food intake may prevent entrainment of  circadian 
genes in the liver and gastrointestinal tract that normally occur in response to caloric restriction.
Fumagillin induces energy conservation. To explore the effects of fumagillin on energy balance, we used anoth-
er cohort of rats for analysis of body (rectal) temperatures. To simplify this study, we chose a single dietary 
intervention time point (4 weeks) intermediate between the 2- and 8-week time points shown in Figures 1–4. 
The weight loss profile of all rats studied after 4 weeks of intervention is shown in Supplemental Figures 2, 
A–D. HF/FG fed animals had significantly lower body temperatures compared with either HF/PF- or HF-fed 
Figure 5. Fumagillin feeding affects feeding rhythm and expression of circadian genes. Wistar rats were fed a HF diet for 12 weeks and then subjected 
to an intervention period of 4 weeks, during which they consumed HF diet ad libitum (HF), HF diet with fumagillin (HF/FG), or an amount of HF food 
matched to the amount consumed by the HF/FG group (HF/PF). (A–C) Average food intake measured in these 3 groups of rats daily over 4 time periods 
after daily food provision at ZT6:00 (1:00 pm). The periods sampled were ZT6:00–10:00, ZT10:00–14:00, ZT14:00–2:00, and ZT2:00–6:00, equating to 1–5 
pm, 5–9 pm, 9 pm–9 am, and 9 am–1 pm. n = 3, 5, and 4 for HF, HF/FG, and HF/PF groups, respectively. HF group compared with HF/FG or HF/PF groups for 
total food intake; P < 0.000009. HF group compared with HF/FG group for food intake during ZT6:00–2:00 (1 pm–9 am); P < 0.04. HF group compared with 
HF/PF group for food intake during all time periods except for ZT10:00–14:00 (5–9 pm); P < 0.04. HF/FG group compared with HF/PF group for food intake 
during all time periods except for ZT2:00–6:00 (9 am–1 pm); P < 0.002. (D) Expression levels of Bmal1 (upper panel), Clock (middle panel), and Per1 (lower 
panel) transcripts in liver, stomach, duodenum, jejunum, ileum, colon, cecum, epididymal white adipose tissue (EWAT), and mesenteric white adipose 
tissue (MWAT). Samples were collected after 10 days of diet intervention. Data represent means ± SD for n = 3, 5, and 4 for HF, HF/FG, and HF/PF groups, 
respectively. *P < 0.05 when compared with the other 2 groups. #P < 0.05 when compared with the HF group. +P < 0.05 when compared with HF/FG group. 
For all panels, 2-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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rats at both time points sampled in the dark cycle, and at 2 of 4 time points sampled in the light cycle (n = 7 
rats/treatment group; Figure 6A).
The reductions in physical activity and oxygen consumption (Figures 3 and 4), along with body tem-
perature (Figure 6A), induced by fumagillin feeding could suggest a decrease in sympathetic tone. To test 
this, we collected urine samples and measured catecholamine levels. HF/FG feeding led to a significant 
reduction of  urine catecholamine levels relative to either the HF or HF/PF group (Figure 6B), consistent 
with a suppression of  sympathetic tone.
The chronic lowering of  body temperature in the HF/FG group suggests that fumagillin may induce 
a condition resembling torpor, as experienced in hibernating animals, although it should be emphasized 
that physical activity of  the HF/FG group, while clearly reduced compared with the HF/PF group, was 
similar to that of  the HF group (Figures 3 and 4). To investigate this notion further, we measured expres-
sion of  torpor-related genes in the liver (14, 15). Two weeks after intervention, several genes considered 
as molecular markers of  torpor, including fibroblast growth factor 21 (FGF21), carboxyl ester lipase (Cel), 
pancreatic colipase (Clps), pancreatic lipase (Pnlip), and pancreatic lipase–related protein 2 (Pniprp2), 
trended to be expressed at higher levels in the livers of  animals in the HF/FG group compared with 
either the HF or HF/PF group (Figures 6, C and D). These changes did not achieve statistical signifi-
cance due to the varying responses among individual HF/FG animals and to the fact that the transcripts 
were undetectable in livers of  several rats in the HF/PF control group, similar to what has been reported 
for induction of  torpor genes by FGF21 (14). These results demonstrate that HF/FG feeding induces a 
Figure 6. Fumagillin treatment affects body temperature, expression of torpor-related genes, and urine catecholamines. Rats were fed the HF diet for 12 
weeks and then subjected to an intervention period of 2 or 4 weeks, during which time they consumed HF diet ad libitum (HF), HF diet with fumagillin (HF/
FG), or an amount of HF food matched to the amount consumed by the HF/FG group (HF/PF). (A) Following 4 weeks of diet intervention, rectal tempera-
tures were measured in rats at 6 time points over a 20-hour period that covered light and dark cycles. Data are presented as mean ± SD for n = 7 per group. 
*P < 0.05 when compared with the other 2 groups. (B) Urine catecholamine levels, normalized to creatinine (CREA), in samples collected after 4 weeks of 
diet intervention. Data are presented as mean ± SD for n = 8 per group. *P < 0.05 when compared with the other 2 groups. (C and D) Hepatic expression of 
torpor-related transcripts after 2 weeks of diet interventions. Data are presented as mean ± SD. n = 6 for each group. +P = 0.057 when compared with HF 
group. Two-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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chronic change in energy balance that is not explainable simply by a reduction of  food intake, since these 
changes were not observed in HF/PF animals.
Fumagillin treatment influences gastrointestinal energy harvest and secretion of  gastrointestinal hormones, but not 
gastric emptying. Results summarized so far leave us with the question of  how HF/FG feeding causes more 
extensive and sustained weight loss compared with HF/PF feeding, despite the effect of  the former inter-
vention to lower energy expenditure and physical activity. One possibility is that fumagillin could alter gut 
function and energy harvest. Consistent with this idea, we found — using bomb calorimetry — that HF/
FG rats retained significantly more energy in their feces than either the HF or HF/PF groups (Supplemen-
tal Figure 5A), suggesting that fumagillin alters energy extraction/absorption in the gut.
We also performed fasting/refeeding experiments in HF/FG- and HF/PF-fed animals and mea-
sured the mass of  residual, dried stomach contents 72 hours after the conclusion of  the meal (16). At 
that time point, members of  the HF/FG group had significantly more residual food in the gut compared 
with the HF/PF group (Supplemental Figure 5B). However, it should be noted that it took approximate-
ly 1.5 hours for animals in the HF/FG group to finish eating all of  the food provided, compared with 
only 10 minutes for animals in the HF/PF group. In a separate experiment, we gave liquid acetamino-
phen via oral gavage, measured the rate of  appearance of  acetaminophen in the serum, and observed 
no significant differences between the 2 groups (Supplemental Figure 5C). In aggregate, these findings 
suggest no intrinsic difference in gastric emptying or absorptive function; rather, they suggest that the 
greater retention of  food in the stomach of  HF/FG rats is related to their slower rate of  food consump-
tion rather than a change in gastric-emptying rate.
Finally, since reductions of  caloric intake and body weight occurred within 2 days of  initiation of  HF/
FG feeding, we investigated the possible involvement of  gastrointestinal hormones known to affect food 
intake and energy balance. Blood samples were collected 2 days after the start of  interventions, at ZT6:00 
(1 pm) for the HF and HF/FG groups and at ZT0:00 (7 am) for the HF/PF group. The HF/FG group had 
significantly higher levels of  GLP-1 than the HF/PF group (Supplemental Figure 6A); GLP-1 is thought to 
work centrally to suppress food intake. In addition, compared with the HF group, HF/PF animals exhib-
ited a clear increase in circulating levels of  ghrelin, a hormone that promotes food intake, but this increase 
was not observed in HF/FG rats (Supplemental Figure 6B). The ghrelin/GLP-1 ratio was significantly 
higher in HF/PF compared with HF rats (Supplemental Figure 6C). Levels of  adiponectin were also sig-
nificantly higher in HF/FG compared with HF and HP/PF animals (Supplemental Figure 6D). Together, 
these data are consistent with a potential role of  GLP-1 in mediating the decrease in food intake in HF/
FG rats. This, coupled with the lack of  increase in ghrelin in HF/FG animals despite their caloric restric-
tion, could contribute to the more relaxed feeding behavior of  animals in the HF/FG group. Short-chain 
fatty acids (SCFA) produced by the microbiota have been linked previously to gut hormone secretion (17, 
18). We found that levels of  acetate in cecal contents harvested from HF/FG rats were significantly higher 
than in either the HF or HF/PF groups; propionate and butyrate levels followed the same trend, but the 
differences did not achieve statistical significance (Supplemental Figure 6E). SCFA are thought to bind to 
GPCRs GPR41 and GPR43 in L cells of  the small intestine to stimulate GLP-1 release (19).
Metabolomics analyses. Metabolomics analyses revealed a wide array of  differences between HF/FG and 
HF/PF groups, which are likely due to the differences in feeding behavior (Supplemental Table 2). For all 
animals, food was provided once daily at ZT6:00 (1 pm). Based on our finding of  clear differences in feeding 
behavior between HF/FG and HF/PF animals (Figures 3 and 4), this meant that the HF/PF group was 
eating all its food in a rapid fashion and then experiencing a long fasting period prior to sacrifice the next day 
at ZT6:00 (1 pm). In contrast, the HF/FG group was nibbling food slowly throughout the night, meaning 
that these animals were less acutely fasted at the time of  sacrifice. As a result, the HF/PF group had large 
increases in fatty acid–derived acylcarnitines and ketone metabolites compared with the HF or HF/FG 
groups, consistent with activation of  lipolysis and oxidation of  fatty acids, a hallmark of  the fasted state 
(Supplemental Table 2). Moreover, analysis of  urine samples indicated significant reduction of  urea nitrogen 
and urea levels (normalized to creatinine [CREA] levels) in the HF/FG compared with HF/PF and HF 
groups (Supplemental Figure 7, A and B), as well as increases in levels of  multiple urinary amino acids (Sup-
plemental Figure 7C); these results are suggestive of  reduced rates of  amino acid oxidation in HF/FG rats 
and possible caloric spilling that could contribute to the more sustained weight loss in the HF/FG group.
Two other metabolic differences between the HF/FG and HF/PF groups were particularly notewor-
thy. First, we found that HF/FG-treated rats had levels of  glycogen in liver and skeletal muscle that were 
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.99453
R E S E A R C H  A R T I C L E
similar to animals fed on HF diet ad libitum, whereas liver and muscle glycogen levels were significantly 
lower in the HF/PF group (Figure 7, A and B). These findings may help to explain the selective decrease 
in liver weight noted in the HF/PF compared with the HF and HF/FG treatment groups (Figure 2B). 
Consistent with these findings, levels of  phosphorylated glycogen synthase kinase 3β (GSK3β) were sig-
nificantly increased in the livers of  HF/FG compared with HF/PF rats at both the 2- and 8-week time 
points of  the intervention (Figure 7C) and in skeletal muscle at 8 weeks (data not shown); phosphory-
lation of  GSK3β inhibits its activity and leads to less inhibitory phosphorylation of  glycogen synthase, 
contributing to more active glycogen synthesis. Second, animals that ate the HF/FG diet had significantly 
Figure 7. Fumagillin treatment affects glycogen levels, but hepatic glycogen is not the mediator of fumagillin-induced changes in feeding behavior. 
First 3 panels: rats were fed HF or SC diet for 12 weeks and then subjected to dietary intervention periods of 2 or 8 weeks, as described in Figure 1C. Liver 
and muscle samples were collected for measurement of glycogen levels or phospho-GSK3β levels at ZT6:00 (1 pm) at the 2-week or 8-week time points. 
Last 3 panels: rats were fed on HF diet for 12 weeks and then subjected to an intervention period of 4 weeks, during which rats were fed HF diet with 
fumagillin ad libitum (HF/FG) or an amount of HF food matched to the amount consumed by the HF/FG group (HF/PF), in the presence or absence of 
methionine restriction (MR). Liver samples were collected at ZT6:00 (1 pm), immediately prior to the normal once-daily provision of food. (A) Hepatic 
glycogen levels. Data are mean ± SD for n = 6 for each group. *P < 0.05 when compared with other groups at each time point. (B) Glycogen levels in gastroc-
nemius muscle. Data are mean ± SD for n = 6 for each group. *P < 0.05 when compared with other groups at each time point. (C) Ratio of phosphorylated 
GSK3β compared with total GSK3β in liver. Data are mean ± SD for n = 6 for each group. *P < 0.05 when compared with other groups at each time point. 
(D) Immunoblot analysis of liver samples obtained from rats treated with adenoviruses expressing either a Flag-tagged C-terminal deleted version of the 
muscle isoform of glycogen-targeting subunit of protein phosphatase 1 (GmΔC-Flag) (21) or β-galactosidase (βGal) and continuously fed the indicated diets 
for 1 week. (E) Hepatic glycogen levels in rats treated with the indicated adenoviruses. Data are mean ± SD for n = 5–7 animals per group. *P < 0.02 when 
compared with the other groups. (F) Changes in RER in response to daily provision of food at ZT6:00 (1 pm) (downward arrow) in rats fed the indicated 
diets and treated with the indicated adenoviruses. All diets in this experiment contained normal methionine levels. n = 5–7 for each treatment group. For 
all panels, 2-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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lower liver methionine levels than either the HF or HF/PF group (Supplemental Table 2). This obser-
vation suggests that MetAP2, the fumagillin target enzyme that cleaves N-terminal methionine residues 
from nascent proteins, is a significant regulator of  steady state methionine levels.
Modulation of  hepatic glycogen and/or dietary methionine levels does not affect feeding behavior of  pair-fed ani-
mals. Prior studies have implicated liver glycogen (19) and dietary methionine (20) as modulators of  feeding 
behavior in rodents. This led us to test the hypothesis that the reduced hepatic glycogen levels and/or elevat-
ed methionine levels in HF/PF rats contribute to their sense of  starvation and abrupt feeding behaviors. To 
test this idea, we used recombinant adenovirus to overexpress a modified version of  the muscle isoform of  
the glycogen-targeting subunit of  protein phosphatase-1, known as GmΔC-Flag. We have previously demon-
strated that adenovirus-mediated expression of  this construct in the livers of  streptozotocin-treated diabetic 
rats raises hepatic glycogen levels, lowers blood glucose levels, and attenuates hyperphagia (21). The AdC-
MV-GmΔC-Flag adenovirus was injected into HF/PF rats 4 weeks after initiation of  their feeding protocol, 
and their behaviors in metabolic cages were compared with those of  HF/PF or HF/FG rats injected with 
a control (AdCMV–β-galactosidase; AdCMV-βGal adenovirus (n = 5–7 animals/treatment group). Injec-
tion of  AdCMV-GmΔC-Flag into HF/PF rats increased expression of  GmΔC, as expected (Figure 7D), 
and raised liver glycogen to the levels found in HF/FG rats; levels in both groups were significantly greater 
than those observed in HF/PF rats injected with the control AdCMV-βGal vector (Figures 7E). However, 
“clamping” liver glycogen at elevated levels in HF/PF rats did not change feeding behavior. Like members 
of  the HF/PF/AdCMV-βGal control group, these animals exhibited abrupt increases in ambulatory activi-
ty, VO2, and RER in response to provision of  food (representative of  all of  these responses; only the changes 
in RER are shown in Figure 7F).
We also tested the potential role of  reduced hepatic methionine levels on feeding. To do this, we created 
a HF, methionine-restricted (HF/MR) diet in an attempt to mimic the effects of  fumagillin on lowering of  
methionine levels (Supplemental Table 1). We pair-fed the HF/MR diet to match the rate of  HF/FG food 
intake (HF/PF, MR). HF/MR feeding was performed in rats treated with AdCMV-GmΔC-Flag or AdC-
MV-βGal (for levels of  hepatic expression of  GmΔC achieved with the recombinant virus, see Figure 7D; for 
liver glycogen levels, see Supplemental Figure 8A). There were no statistically significant differences in calor-
ic intake (kcal/g body weight) or body weight among the 3 study groups (HF/FG + AdCMV-βGal; HF/
PF, MR + AdCMV-βGal; HF/PF, MR + AdCMV-GmΔC-Flag; data not shown). HF/PF, MR–fed animals 
exhibited a trend for lowering of  hepatic methionine levels compared with HF/FG animals (Supplemental 
Figure 8B), but methionine restriction did not significantly suppress the burst in RER or heat production 
in response to HF/PF feeding, regardless of  whether liver glycogen levels were maintained at high levels 
(data for RER shown in Supplemental Figure 8C; n = 5–7 animals evaluated for each parameter/treatment 
group). Thus, we conclude that fumagillin-mediated increases in hepatic glycogen content or decreases in 
methionine levels do not explain differences in feeding behavior of  HF/FG compared with HF/PF rats.
The gut microbiota is implicated in fumagillin-mediated expression of  genes involved in energy conservation 
but not appetite suppression. The observed changes in energy extraction, cecal SCFA concentrations, 
and gut hormone levels suggest a testable hypothesis — namely, that fumagillin may exert effects on 
the host, in part, by altering the functional properties of  the gut microbiota. 16S rRNA gene sequenc-
ing of  fecal samples of  HF/FG and HF/PF rats did not reveal significant differences between the 
composition of  their gut microbiota. However, this metric does not reflect changes in composition at 
the strain-level or changes in gene expression that could be induced by fumagillin. Therefore, we per-
formed microbiota transplant experiments to directly test whether the microbiota was causally related 
to the physiologic and metabolic phenotypes produced by fumagillin. Male, 10- to 12-week-old, germ-
free C57BL/6J mice were switched to the HF diet for 2 weeks (run-in period). Two groups of  5 germ-
free mice each were colonized with cecal microbiota harvested from a HF/FG rat, while 2 groups of  
5 germ-free mice each received transplanted cecal microbiota from a HF/PF rat. The selected micro-
biota donors were representative of  their treatment groups, as judged by their body weight and feeding 
phenotypes, as well as by the results of  a phylogenetic dissimilarity metric applied to bacterial 16S 
rRNA datasets generated from their cecal microbial communities (Supplemental Figure 9A). The first 
group of  gnotobiotic mice colonized with HF/FG or HF/PF rat donor microbiota were fed the HF 
diet ad libitum, and food intake was measured over 3 time periods (ZT2:00–6:00, ZT6:00–14:00, and 
ZT14:00–2:00, equivalent to 9 am–1 pm, 1 pm–9 pm, and 9 pm–9 am, respectively). No significant 
differences in total food intake or food intake as a function of  time period were observed in any of  
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the groups of  recipient mice (Figure 8, A and B). In a second set of  experiments, germ-free mice colo-
nized with cecal microbiota from HF/FG or HF/PF rats were fed ad libitum for 6 days and were then 
subjected to a 10% reduction in food portion relative to the amount consumed during the ad libitum 
feeding period. Caloric restriction did not elicit significant differences in the temporal pattern of  feed-
ing or total food intake in animals harboring microbiota from HF/FG versus HF/PF mice (Figure 8, C 
and D). Specifically, caloric restriction of  the 2 groups of  mice caused a similar increase in aggressive 
feeding behavior (occurring in the ZT6:00–10:00 [1–5 pm] period immediately after food provision) 
in the 2 groups of  animals. In both experiments, there was no difference in body weight between the 2 
groups of  mice that received either HF/FG or HF/PF rat donor microbiota (Supplemental Figure 10).
We subsequently characterized torpor-related and circadian gene expression in livers of  the mice stud-
ied in Figure 8, A–D. We found that animals containing microbiota from HF/FG rats exhibited a strong 
trend for induction of  torpor marker genes such as Cel, Clps, and Pnlip, in both the ad libitum–fed and 
calorically restricted states, relative to mice harboring microbiota from HF/PF rats (Figure 8E). In contrast, 
no differences were observed in hepatic expression of  the circadian genes Bmal1 and Clock in mice harbor-
ing microbiota from HF/FG versus HF/PF rats (Figure 8F). These findings suggest that the aggressive 
pattern of  feeding behavior induced by caloric restriction, as well as the resulting changes in circadian gene 
expression, are regulated independent of  the microbiota, whereas the gut community appears to have a role 
in regulating expression of  torpor genes, perhaps relating to the energy preservation phenotype observed in 
response to fumagillin-induced caloric restriction.
To understand whether the abundance of  certain gut bacterial species was correlated with these trans-
missible phenotypes, we performed indicator species analyses (22, 23) using 16S rRNA gene sequencing 
datasets generated from fecal samples collected 2, 5, and 11 days after gavage of  the rat donor gut micro-
bial community, as well as cecal samples obtained at the time of  sacrifice on day 11. Indicator species 
analysis identifies organisms associated with particular habitat types using the indicator species value (23). 
Using this approach, we identified 97%ID OTUs (Operational Taxonomic Units sharing ≥ 97% nucleo-
tide sequence identity) as associated with fumagillin-treated donor microbiota if  they (i) were significantly 
more likely to be present in samples taken from mice colonized with this rat donor’s microbiota and/or (ii) 
had significantly greater relative abundance in recipient mice harboring this community. We found eleven 
97%ID OTUs (across fecal samples and cecal samples taken at sacrifice) that distinguish the groups of  
animals that exhibited divergent torpor gene expression profiles (Supplemental Figure 9 and Supplemental 
Table 3). Additional indicator species analyses performed on the cecal microbiota of  the treatment groups 
from which the donors were selected yielded 1 bacterial OTU among the 11 (OTU no. 296726, unclassified 
phylogeny) that was indicative of  fumagillin treatment (P < 0.005, uncorrected; Supplemental Figure 9B).
Finally, to test whether fumagillin has effects on energy balance independent of  the gut microbiota, we 
fed another cohort of  uncolonized, germ-free mice with HF or HF/FG diets. A significant decrease in body 
weight was observed in animals fed the HF/FG diet compared with mice receiving the HF diet with no 
fumagillin added. The difference was already significant within 2 days of  administration of  the diets, and 
it remained significant through 9 days of  feeding (Figure 9). We then swapped the diets so that the group 
fed the HF/FG diet for the first 9 days was now eating HF diet without fumagillin, and the group eating 
the HF diet was now consuming the HF/FG diet. Rapid weight loss was observed in the group switched to 
the HF/FG diet, whereas weight regain was observed in the group switched to the HF diet. In aggregate, 
the studies shown in Figures 8 and 9 support the conclusion that fumagillin confers its effects on feeding 
behavior by mechanisms that are independent of  the gut microbiota.
Discussion
In the current study, we have used a model of  DIO in rats to study the effects of  the natural product 
MetAP2 inhibitor fumagillin on weight loss and energy balance. We confirmed the findings of  a previous 
study in DIO mice (7) in DIO rats by showing that fumagillin causes a larger amount of  weight loss than 
pair feeding. Moreover, fumagillin feeding maintained weight loss over a 30-day period in DIO mice (7) 
and out to 8 weeks in the current DIO rat study. In contrast, the body weight of  pair-fed animals in both 
studies began to rise over the course of  the intervention period and were on a trajectory to return to baseline 
levels. We demonstrate that fumagillin induces sustained weight loss by mechanisms that reach beyond 
those activated by simple caloric restriction to include a remarkable set of  physiologic, behavioral, hormon-
al, and biochemical changes.
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The most striking finding of  the current study was a clear effect of  fumagillin on feeding behavior. 
Whereas HF/PF rats consumed food rapidly and aggressively upon presentation in our once-daily feeding 
paradigm, HF/FG rats ate much more slowly and ultimately consumed less food than rats fed the HF diet 
ad libitum. This nonchalant feeding behavior of  HF/FG rats was linked to differences in expression of  key 
circadian genes in multiple visceral organs compared with HF/PF rats (Figure 5D). These findings suggest 
that fumagillin-induced alterations in feeding behavior and food intake may prevent entrainment of  circadi-
an genes in the liver and gastrointestinal tract in response to caloric restriction. We note that the aggressive 
feeding response observed in HF/PF rats occurred when they were fed daily at ZT6:00 (1 pm), which is in 
the middle of  the light cycle, when feeding is suppressed in HF- or HF/FG-fed rats. We became concerned 
that the perception of  a limited portion size in HF/PF rats may have caused anxiety, contributing to the 
aggressive response. However, when portion size was reduced to a similar extent in HF/FG rats, aggressive 
feeding was not activated. Thus, if  perception of  portion size is a factor in aggressive feeding of  HF/PF rats, 
fumagillin prevents this response. Consistent with this reduction in aggressive food-seeking behavior in rats, 
treatment with the fumagillin analog beloranib was found to strongly reduce severe hyperphagia-related 
Figure 8. Feeding rhythms and hepatic torpor and Clock gene expression of gnotobiotic mice receiving cecal microbiota transplants from HF/FG or HF/
PF rats. All of the experiments in A–F, are from n = 5 mice/group. (A) Daily accumulated food intake of mice colonized with the cecal microbiota of a HF/FG 
rat. HF diet was provided ad libitum. (B) Daily accumulated food intake of mice colonized with the cecal microbiota of a HF/PF rat. HF diet was provided ad 
libitum. (C) Daily accumulated food intake of mice colonized with the cecal microbiota from a HF/FG rat. HF diet was provided ad libitum from experimen-
tal day 1–5 and then restricted by 10% from day 6–10. (D) Daily accumulated food intake of mice that were the recipients of a cecal microbiota transplant 
from a HF/PF rat. HF diet was provided ad libitum from day 1–5 and then restricted by 10% from day 6–10. (E) Expression of hepatic torpor genes in mice 
from the studies shown in A–D. +P = 0.06 when compared with HF/FG ad libitum/CR group. (F) Expression of hepatic circadian genes in mice from the 
studies shown in A–D. *P < 0.05 when compared with the corresponding calorically restricted groups. In E and F, data are presented as mean ± SD, and 
2-tailed, unpaired t tests were performed. P < 0.05 with a Bonferroni correction was used to define statistical significance among groups.
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body weight and aggressive feeding behaviors in patients with Prader-Willi syndrome, a condition character-
ized by extreme hunger, low metabolic rate, and profound, life-threatening obesity (10).
Metabolic cage studies revealed several physiologic changes in HF/FG compared with HF/PF rats. 
The aggressive feeding behavior of  HF/PF rats was reflected in sharp increases in VO2, heat production, 
physical activity, and RER immediately after provision of  food at ZT6:00 (1 pm) in our once-daily feeding 
regimen. In addition, aggregate measurements over 24 hours revealed clear and sustained increases in VO2, 
heat production, and physical activity but not RER in HF/PF compared with HF/FG mice. Thus, despite 
the larger and more sustained weight loss in HF/FG rats, physical activity and energy expenditure were 
decreased compared with the HF/PF group. In contrast to the effects of  caloric restriction in HF/PF rats 
to trigger increases in food-seeking behavior and physical activity resulting in increased energy expenditure, 
fumagillin acts in the presence of  the same degree of  caloric restriction to conserve energy.
We identified multiple metabolic differences between the HF/FG and HF/PF groups, many of  which 
are likely driven by the change in feeding pattern and a more pronounced extent of  fasting in HF/PF ani-
mals. Differences in liver glycogen and methionine levels were investigated further, given that prior studies 
had implicated both in regulation of  feeding behaviors (19–21). However, neither maintenance of  elevated 
liver glycogen levels by recombinant adenovirus–mediated engineering, dietary methionine restriction, nor 
both simultaneously, were able to suppress the aggressive feeding behavior of  HF/PF rats.
Consistent with its effects on multiple measures of  energy expenditure, fumagillin blunts sym-
pathetic tone in the HF/FG compared with the HF/PF group, as evidenced by a clear decrease in 
urine catecholamines. Also consistent with a profile of  energy conservation, body temperatures were 
decreased at multiple time points in both the dark and light cycles in HF/FG compared with HF/PF 
rats. Finally, an array of  genes associated with torpor-like states, including Cel, Clps, Pnlip, and Pnliprp2, 
trended to be induced by fumagillin feeding. A torpor-like phenotype has previously been reported in 
response to FGF21 administration in mice (14); here, we also observed an increase in FGF21 expres-
sion in liver of  HF/FG rats, consistent with increased plasma levels of  FGF21 in obese patients treated 
with the fumagillin analog beloranib (9).
In light of  the surprising finding of  a larger and more sustained degree of  weight loss in HF/FG com-
pared with HF/PF rats, despite the equally reduced food intake and lower energy expenditure observed in 
the former group, we investigated potential contributions of  altered gastrointestinal function or activities of  
the gut microbiota in mediating these effects. We found no evidence of  differences in gastric emptying or 
gastrointestinal absorptive function in HF/FG compared with HF/PF rats, but analysis of  gross fecal heat 
capture by bomb calorimetry revealed that HF/FG rats retained significantly more energy in their feces than 
either the HF or HF/PF groups, suggesting that fumagillin alters gastrointestinal energy extraction/absorp-
tion, contributing to negative energy balance. This finding was complemented by the observed increase in 
levels of  urinary amino acids in HF/FG compared with HF/PF groups, suggestive of  calorie “spilling.”
Figure 9. Cumulative change in body weight in germ-free mice after fumagillin administration. Germ-free mice were provided with HF diet ad libitum 
from day –4 to –1. Thereafter, mice received either HF or HF/FG diets ad libitum from day 0–8. The 2 diets were then switched from day 9–18. Two-tailed, 
unpaired t tests were performed. P < 0.05 was used to define statistical significance among groups.*P < 0.05 between the 2 groups. n = 6/group.
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We also found that, compared with the HF/PF group, the HF/FG group had significantly higher levels 
of  GLP-1 and lower levels of  ghrelin — hormones whose production are affected by SCFA produced by gut 
microbial fermentation (17, 18). The increase in the GLP-1/ghrelin ratio in HF/FG rats is consistent with the 
observed changes in feeding behavior in these animals. These observations led us to test if  fumagillin-induced 
changes in the functional configuration of  the gut microbiota were causally related to feeding behavior and 
energy balance. Transplantation of  cecal microbiota from HF/FG or HF/PF rats to germ-free mice revealed 
no differences in total food intake or feeding behavior when the mice were fed ad libitum. Furthermore, the 
2 groups exhibited the same transition to aggressive feeding behavior when subjected to caloric restriction. 
Consistent with a lack of  effect of  the HF/FG versus HF/PF microbiota on feeding behavior, we found 
that feeding of  germ-free mice with HF/FG diet was sufficient to reduce food intake. Also aligning with 
these findings, liver circadian gene expression was not different between mice colonized with microbiota from 
HF/FG and HF/PF rats, indicating that the ability of  fumagillin to block programming of  these genes in 
response to caloric restriction is not mediated by effects on the gut microbiota. In contrast, induction of  torpor 
genes was observed in mice colonized with cecal contents from HF/FG, but not HF/PF, rats. Only modest 
differences were noted in the structural configuration of  the microbiota of  recipient mice characterized in 
the current study. Future studies of  the microbiota of  larger numbers of  rats subjected to the various dietary 
manipulations described (including comprehensive analyses of  the organismal and gene content of  their gut 
communities, microbial gene expression, and expressed microbial metabolic activities) will be needed to bet-
ter understand the effects of  fumagillin. The same multi-omics approach should also be applied to gnotobiotic 
mouse recipients of  microbiota from multiple rats from each of  the treatment groups, and the results cor-
related with metabolic cage studies, although performing this latter type of  phenotypic analysis is technically 
challenging when mice reside in gnotobiotic isolators. Nonetheless, our current results suggest that the effect 
of  the microbiota to regulate torpor genes may contribute to or serve as a marker of  energy conservation 
during fumagillin feeding.
In sum, these studies define a set of  physiological and behavioral responses to fumagillin that contrib-
ute to a larger and more sustained weight loss response than achieved with caloric restriction alone. Given 
the very high rates of  recidivism typically observed in obese humans that attempt to engage in caloric 
restriction, an implication of  our findings is that more sustained and robust weight loss intervention strate-
gies may emerge from further analysis of  the biological effects of  fumagillin and related compounds.
Methods
Supplemental Methods are available online with this article.
Animals and dietary regimens. Male Wistar rats (150–175 g, ~6 weeks of  age, Charles River Laboratories) 
were singly housed under a 12-hour/12-hour light/dark cycle (lights on at 7 am, also referred to as ZT0:00) 
with free access to water and fed a HF diet or a plant polysaccharide–based SC diet (Envio, catalog 7001) 
for 12 weeks prior to further dietary interventions (Supplemental Table 1). Food intake and body weights 
were monitored weekly during this period. Animals were then subjected to 2, 4, or 8 weeks of  the following 
dietary interventions: (i) HF group; (ii) HF/FG group; (iii) HF/PF group, or (iv) SC group. Food intake 
and body weights were monitored daily at ZT6:00 (1 pm); food was provided to each group once daily 
immediately after weighing at ZT6:00 (1 pm).
The dicyclohexylamine salt of  fumagillin was purchased from Medivet. This material was dissolved in 
1:6 water/ethyl acetate and washed 3 times with 1N phosphoric acid (MedChem Partners). The resulting 
organic solution was treated with activated carbon and sodium sulfite. The solids were then removed by fil-
tration, and the material was condensed on a rotovap (Büchi R-205). The resulting solids were titrated with 
ethyl acetate to yield fumagillin free acid (98.1% purity by LC/MS). The average weight of  rats throughout 
this study was 529 g, and given a dose of  80 mg fumagillin/kg food and an average HF/FG food intake of  
13.8 g/day, the average daily dose of  fumagillin was 2.08 grams of  fumagillin per rat per day.
Multiple cohorts were subjected to these feeding protocols and used for the following studies. At the 
end of  the intervention periods, one cohort was sacrificed for collection of  plasma, liver, gastrocnemius 
muscle, and adipose tissue after i.p. injection of  Nembutal at a dose of  250 mg/kg body weight. All dissect-
ed tissue/organs were rinsed with chilled saline, dried on gauze, and weighed quickly, followed by clamp 
freezing. All biospecimens were stored at –80oC for hormone, metabolomics, or gut microbiota analyses. A 
second cohort of  rats were analyzed by indirect calorimetry and physical activity measurements in meta-
bolic cages for 40 hours, with continued provision of  their respective diets. They were then returned to their 
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home cages for 1 week, followed by analysis of  insulin sensitivity by hyperinsulinemic-euglycemic clamp 
(24). The third and fourth cohorts were subjected to 4 weeks of  dietary intervention and used for measure-
ment of  rectal temperature and additional tissue collection. The fifth cohort of  animals only included HF/
FG and HF/PF groups and were used for measurement of  gastric emptying. The sixth cohort of  animals 
was fed with either HF or HF/MR diets for a 5-week intervention that included treatment with various 
recombinant adenoviruses over the last 7 days. Finally, several cohorts were used for feeding behavior stud-
ies, with food intake monitored at ZT6:00, ZT10:00, ZT14:00, and ZT2:00 (1 pm, 5 pm, 9 pm, and 9 am) 
daily over multiple days.
Hyperinsulinemic-euglycemic clamps. Insulin sensitivity was measured by hyperinsulinemic-euglycemic 
clamps using recently described methods (24). Clamps were performed in conscious unrestrained ani-
mals using swivels and tethers (Instech Laboratories) to allow uninterrupted movement of  the animals 
without disruption of  infusion lines. Hyperinsulinemia was achieved by a primed i.v. infusion (720 mU/
kg/min for 7 minutes) followed by continuous infusion (4 mU/kg/min). Blood was sampled from arte-
rial lines at 5-minute intervals, and glucose levels were quantified (BD Logic Glucose Monitor). Eugly-
cemia, defined as blood glucose above 10% of  individual fasting glycemia, was restored and maintained 
by variable infusion of  30% dextrose. Steady state was achieved approximately 90 minutes after initiating 
hyperinsulinemia and maintained for at least 45 minutes. Rats were euthanized immediately following 
the clamp procedure.
Plasma and tissue metabolomics analyses. Analyses of  plasma acylcarnitines, amino acids, conventional 
metabolites, and hormones, as well as liver and gastrocnemius muscle acylcarnitines, acyl CoAs, cera-
mides, amino acids, and organic acids, were performed as described previously (24–27).
Indirect calorimetry. Indirect calorimetry was performed using an 8-chamber comprehensive lab animal 
monitoring system (CLAMS) (Columbus Instruments). Rats fed on the various diets described above were 
acclimatized to the system overnight prior to measurements collected over a 48-hour period. Food was 
provided to all experimental groups of  rats at ZT6:00 (1 pm) daily, and the light cycle was set from ZT0:00 
(7:00 am) to ZT12:00 (7:00 pm).
Quantitative PCR. Stomach, sections of  intestine, liver, and adipose tissue were collected, snap-frozen 
and stored at –80oC. RNA was harvested using the RNeasy minikit (Qiagen), and cDNA was synthesized 
with the iScript reaction (Bio-Rad). Real-time PCR was performed using the ViiA7 sequence detection sys-
tem and software (TaqMan-based Assay on Demand; Applied Biosystems). Sequences of  all primers used 
for real-time PCR in the study are provided in Supplemental Table 4.
Bomb calorimetry. Fecal samples and pulverized diets were freeze-dried at –35°C for 48 hours using 
a vacuum freeze-dry chamber (Labconco, catalog 7400040, FreeZone Triad Freeze Dry Systems). Sam-
ples were stored under a vacuum at –80°C, and energy content was measured using a semi-micron oxy-
gen bomb calorimeter, calorimetric thermometer, and semi-micro oxygen bomb (models 6725, 6772, and 
1109A, respectively, from Parr Instrument Co.). The energy equivalent (EE) factor for the calorimeter was 
calculated using benzoic acid standards.
Measurement of  gastric emptying. Acetaminophen absorption and gastric emptying experiments were 
performed as described previously (16), with some modifications. Groups of  HF/FG and HF/PF rats 
were followed for 4 weeks. We controlled for the fact that HF/PF rats consumed food more rapidly than 
members of  the HF/FG treatment group by providing food for the final 2 days before the study at ZT12:00 
(7 pm) rather than ZT6:00 (1 pm) (to shorten the feeding cycle). After the 2-day conditioning period, food 
was withdrawn overnight from the HF/FG group, followed by ad libitum refeeding with the HF/FG diet 
from ZT2:00–4:00 (9–11 am) the following morning. The HF/PF group was subjected to the same proto-
col with 1-day offset to allow food intake to be measured for the 2-hour refeeding period in the HF/FG 
group. The amount of  food consumed by the HF/FG group was measured, and the same amount of  HF 
diet was provided to the HF/PF group during its refeeding period. Both groups of  rats were sacrificed after 
their 2-hour refeeding period for measurement of  residual food in their stomachs. After stomach content 
was retrieved and dried at 50oC for 72 hours, the percentage of  food content remaining in the stomach was 
determined from the dry weight of  stomach content divided by the total amount of  food consumed per 
animal, multiplied by 100 (16).
Measurement of  tissue glycogen and GSK3β. Tissue glycogen content was measured as described previous-
ly (25). Levels of  phosphorylated GSK3β were determined using a commercially available kit (Meso Scale 
Discovery; catalog K150CQD-1 for phosphorylated GSK3β and catalog K150CRD-1 for total GSK3β).
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Infusion of  recombinant adenoviruses and immunoblotting. Recombinant adenoviruses (2 × 109 particle/g 
body weight) were infused via tail vein in isoflurane-anesthetized animals. Cyclosporine A (Bedford Labo-
ratories) was given i.p. at a dose of  15 mg/kg on the day before and the day of  adenovirus infusions (25). 
Construction and use of  recombinant adenoviruses containing a modified version of  the muscle isoform of  
AdCMV-GMΔC and AdCMV-βGal have been described previously (21).
Immunoblot analyses were performed using Bio-Rad Criterion TGX gels (catalog 567-1083), according 
to the protein blotting guide provided by Bio-Rad. Anti-Flag M2-HRP (catalog A8592) was purchased from 
MilliporeSigma.
Bacterial 16S rRNA analysis. DNA was isolated from fecal pellets and cecal contents that had been 
collected from rats or mice by bead-beating in 2× buffer A (200 mM NaCl, 200 mM Tris, 20 mM EDTA) 
and phenol/chloroform/isoamyl alcohol, followed by further purification (QiaQuick 96 purification kit; 
Qiagen). PCR amplification of  the V4 region of  bacterial 16S rRNA genes was performed as described 
(28). Amplicons with sample-specific bar codes were pooled for multiplex sequencing with an Illumi-
na MiSeq instrument. Reads were demultiplexed and rarefied to 5,000 reads/sample. Reads sharing 
≥97% nucleotide sequence identity (97%ID) with a reference sequence in the GreenGenes 16S rRNA 
database (http://qiime.org/home_static/dataFiles.html) (29) were assigned to that OTU. Unassigned 
sequences were grouped into de novo 97%ID OTUs. A phylogenetic tree based on the V4-16S rRNA 
sequences was constructed. Indicator species analysis was performed in the statistical software package 
R v.3.2.4 (30) using “indicspecies” (22) to identify 97%ID OTUs that differed in their representation in 
the microbiota of  gnotobiotic mice colonized with cecal microbial communities from HF/FG versus 
HF/PF rats. Significance was determined by 10,000 permutations, and P values were corrected using 
the Benjamini-Hochberg method. A second indicator species analysis was performed using the subset 
of  OTUs identified in the mice to determine whether any of  them was significantly associated with the 
fumagillin-treated or pair-fed rats.
Statistics. For plasma and tissue metabolomics analyses, pairwise comparisons were made with a Bon-
ferroni correction, focusing on the differences in mean values of  each metabolite between intervention 
groups. For other physiological analyses in both rat and mouse experiments, unless mentioned otherwise, 
2-tailed, unpaired t tests were performed. P < 0.05 was used to define statistical significance between 2 
groups, while P < 0.05 with a Bonferroni correction was used to define statistical significance in group 
comparisons involving more than 2 groups.
Study approval. All procedures involving rats were approved by the Duke University IACUC (Duke 
University School of  Medicine). All experiments involving mice were performed using protocols approved 
by the Washington University Animal Studies Committee (Washington University School of  Medicine). 
Details of  protocols used for gnotobiotic mouse experiments are provided in Supplemental Methods.
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